newsfilter
← Latest News
GlobeNewswire·

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soonHOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all